Objectives. To identify payments that involved opioid products from the pharmaceutical industry to physicians.
T he nonmedical use of opioids and overdose mortality have reached unprecedented levels in the United States. 1 To respond to concerns about overprescribing of opioids, the Centers for Disease Control and Prevention recently released chronic pain management guidelines that call on physicians to consider nonopioid pain medications as an alternative to opioids. 2 Additionally, some physicians and pharmaceutical industry representatives have suggested that abuse-deterrent formulations-newly marketed brand-name opioids with pill properties that render misuse more difficult-offer a safer option for prescribers. 3, 4 Under the recently implemented Physician Payments Sunshine Act, drug companies are now required to report all transfers of value ("payments") to US physicians. 5 Research suggests that pharmaceutical company payments promote increased prescribing for marketed brand-name medications, even when payments are of low monetary value (e.g., industry-sponsored meals). 6 To date, industry payments to physicians involving opioids have not been studied and deserve further examination because they may impede national efforts to reduce overprescribing. It is currently unclear which opioids are most heavily marketed, to whom, and in exchange for which physician activities. The extent to which abuse-deterrent formulations and nonopioid alternatives are marketed is also poorly understood. For the first time, exhaustive data on payments are now available through the Open Payments program database implemented under the Physician Payments Sunshine Act. 5, 7 We used this novel data set to characterize industry payments to physicians related to opioid marketing.
METHODS
We extracted all payments between August 1, 2013 (when mandated reporting began), and December 31, 2015, that listed a US Food and Drug Administration (FDA)-approved opioid product. We included buprenorphine but examined buprenorphine and buprenorphine/naloxone marketed for addiction treatment separately from the buprenorphine transdermal patch marketed for pain control. We excluded remifentanil (which is marketed exclusively for anesthesia) and 2 fentanyl products (1 marketed exclusively for anesthesia, and 1 marketed exclusively for in-hospital pain).
We also identified payments involving FDA-recognized abuse-deterrent opioid formulations. 8 For comparison with a nonopioid class of pain medications, we quantified payments for all actively marketed nonsteroidal anti-inflammatory drugs (NSAIDs) in the database. We chose NSAIDs for this comparison because unlike other medication classes used for pain that have additional indications (e.g., medications marketed not only for pain but also for depression or neuralgia), NSAIDs are almost exclusively used for pain control.
We limited the current analysis to nonresearch payments to physicians; we excluded research payments, which are made in association with established research protocols, do not explicitly target prescribing behaviors, and may be provided to physicians not actively practicing medicine. We summarized payments in terms of total dollars and number of payments made and identified changes from 2014 to 2015 (the 2 years for which all 12 months of data were available). We used medians, interquartile ranges (IQRs), and ranges as a result of heavily skewed distributions to examine payments according to opioid product, abuse-deterrent formulation, nature of payment (i.e., physician activity leading to the payment), state, and physician specialty. We also assessed payments to physicians receiving the top 1% of payments for opioids. We used Stata version 13.1 (StataCorp LP, College Station, TX) for analyses.
RESULTS
Over the study period, 375 266 nonresearch payments involving a marketed opioid were made to 68 177 physicians, totaling $46 158 388. The 5 opioid products constituting the greatest proportion of payments were fentanyl ($21 240 794; 46.0% of total dollars), hydrocodone ($7 123 421; 15.4%), buprenorphine transdermal patch ($5 141 808; 11.1%), oxycodone ($4 487 978; 9.7%), and tapentadol ($4 296 130; 9.3%). Overall, payments for FDA-approved abuse-deterrent formulations totaled $9 352 959 (20.3%), and payments for buprenorphine or buprenorphine/naloxone marketed for addiction treatment totaled $4 561 729 (9.9%). By comparison, payments for NSAIDs amounted to $13 758 385 (not included in previous totals).
Speaking fees or honoraria constituted the largest proportion of payments in dollars, whereas payments involving food and beverage were the most common (Table 1) (Table A , available as a supplement to the online version of this article at http://www.ajph.org). These physicians collectively received $38 073 796 (82.5% of total payments) during the study period.
Physicians specializing in anesthesiology received the most in total annual payments (median = $50; IQR = $16-$151; n = 4339), followed by physical medicine and rehabilitation (median = $48; IQR = $14-$145; n = 3502) and pain medicine (median = $43; IQR = $12-$125; n = 3090). Physicians specializing in family medicine received the largest total number of payments (n = 20 592).
DISCUSSION
According to the Association of American Medical Colleges, there were 829 962 active physicians in the United States at the beginning of the study period in 2013 9 ; thus, our results suggest that 1 in 12 physicians received an industry payment involving an opioid during the 29-month study period. Although half of all the annual payments were $15 or less, even small payments (including meals) are associated with increased prescribing of marketed products. 6 FDA-approved abusedeterrent formulations, which have properties expected to render misuse less likely, constituted only one fifth of the total payments, suggesting that such medications may not be as heavily marketed as other opioids are. Additionally, despite Centers for Disease Control and Prevention recommendations to consider use of nonopioid medications for pain, NSAIDs, a prominent family of nonopioid pain medications, were not as heavily marketed as opioids were.
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Fentanyl was the most common opioid involved in payments to physicians. National data implicate fentanyl in a rapidly increasing number of overdose deaths, although most are caused by illicitly manufactured fentanyl. 10 Further studies should clarify the extent to which industry payments contribute to prescribing patterns and overdose rates across geographic regions, particularly given the heterogeneity we observed in payments among states. Although payment amounts in dollar terms were greatest to physicians specializing in anesthesiology, physical medicine and rehabilitation, and pain medicine-specialists with expertise in pain management-family medicine physicians received the largest number of payments, indicating extensive marketing of opioid products to primary care physicians. Because there were 108 917 active family physicians in the United States in 2013, 9 our data highlight that nearly 1 in 5 received an opioid-related payment.
A limitation of this study was the absence of further details about industry-physician interactions; some payments may have supported education on appropriate prescribing behaviors. 11 One tenth of the payments involved buprenorphine marketed for addiction treatment, which may have resulted in improved education on addiction care. Risk Evaluation and Mitigation Strategies programs imposed by the FDA require education on extended-release/long-acting opioids and on transmucosal fentanyl products, and some industry payments to physicians may have been related to this regulation. Another limitation was that some abusedeterrent formulations were approved partway through the study period; in future years, such medications might be associated with a greater portion of industry payments.
PUBLIC HEALTH IMPLICATIONS
To our knowledge, this was the first large-scale examination of industry payments involving opioids. Financial transfers were substantial and widespread and may be increasing in number and value. Although opioid prescribing declined nationally during the study period, 12 these results should prompt an examination of industry influences on prescribing amid an ongoing opioid crisis. Further research should examine whether payments are related to opioid misuse and overdose, and policymakers might consider whether caps should be imposed on certain payments. 
